Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | IDE | P14735 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 2/20 | 0.60 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.60 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.59 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.59 |
| ▸ | F2 | P00734 | 1/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.59 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20005095 | 1.00 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL24653244 | 1.00 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL13223690 | 1.00 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL12573219 | 0.98 | TDP1 (0.68) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL26902859 | 0.97 | TDP1 (0.69) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL18779801 | 0.94 | TDP1 (0.78) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL23074456 | 0.93 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL24653263 | 0.93 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL20634852 | 0.92 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL15949804 | 0.92 | TDP1 (0.72) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020081572-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| US-20150132780-A1 | MELITTIN PEPTIDE CONJUGATES AND METHODS EMPLOYING SAME | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2015-05-14 | — | — | US | disclosed |
| US-20140287440-A1 | Melittin Peptide Conjugates and Methods Employing Same | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20130143239-A1 | Melittin Peptide Conjugates And Methods Employing Same | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8455185-B2 | Enzymatic detection techniques | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-7964340-B2 | One-step enzymatic and amine detection technique | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-RE42275-E1 | Peptidomimetic inhibitors of PSMA, compounds comprising them, and methods of use | CANCER TARGETED TECHNOLOGY LLC (US) | 2011-04-05 | — | — | US | disclosed |
| US-RE42275-E1 | Peptidomimetic inhibitors of PSMA, compounds comprising them, and methods of use | CANCER TARGETED TECHNOLOGY LLC (US) | 2011-04-05 | — | — | US | disclosed |
| US-7906276-B2 | Enzymatic detection techniques | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| US-20090226938-A1 | One-Step Enzymatic and Amine Detection Technique | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-20090170218-A1 | METHODS FOR DETECTION OF CYCLOSPORIN A | DADE BEHRING INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-7521226-B2 | One-step enzymatic and amine detection technique | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20070202537-A1 | BIOMARKERS FOR ALS | PROSETTA CORPORATION | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170218-A1 | METHODS FOR DETECTION OF CYCLOSPORIN A | CHP1, PPP3R1, SERPINA6 | TDP1 3662/4885MEN1 3207/4885ABL1 4252/4885 |
| US-20070202537-A1 | BIOMARKERS FOR ALS | SOD1, SOD3, GPX1 | TDP1 212/4885MEN1 4249/4885ABL1 4827/4885 |
| US-20130143239-A1 | Melittin Peptide Conjugates And Methods Employing Same | VIP, DNPEP, HM13 | TDP1 4569/4885MEN1 535/4885ABL1 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.